Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | GLS | O94925 | 12/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15380319 | 1.00 | USP30 (0.46) | USP30GPR119GLSSLC6A2TACR1 | |
| SCHEMBL15379933 | 0.95 | GPR119 (0.44) | USP30GPR119POLB | |
| SCHEMBL15378359 | 0.89 | GLS (0.44) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15530893 | 0.89 | GLS (0.44) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15379867 | 0.86 | GLS (0.44) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15379700 | 0.86 | GLS (0.44) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15379588 | 0.85 | GLS (0.43) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15530508 | 0.85 | GLS (0.43) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15531078 | 0.85 | GLS (0.48) | GLSSLC6A2TACR1OPRM1HTR2B | |
| SCHEMBL15379291 | 0.85 | GLS (0.48) | GLSSLC6A2TACR1OPRM1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150141398-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2847181-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8975398-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141398-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885GLS 26/4885 |
| US-20170065575-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885GLS 26/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885GLS 26/4885 |
| US-20130303509-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885GLS 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.